 |
|
 |
| GenoMed Finds NIH's Latest ACE Inhibitor Study ("PEACE") Also Fatally Flawed |
FOR IMMEDIATE RELEASE
Contact:
David Moskowitz MD
CEO, GenoMed, Inc.
tel. 314-983-9933
ST. LOUIS, November 10, 2004-- GenoMed, Inc -- ("the Company" or "GenoMed") (National Quotation Bureau's Pink Sheets Symbol GMED), a St. Louis, Missouri-based medical genomics and Next Generation DM(tm) company, announced today that the PEACE study published in tomorrow's New England Journal of Medicine has the same fatal research flaw as the ALLHAT study published two years ago.
The PEACE study, like ALLHAT, is being interpreted to show that ACE inhibitors have nothing special to offer patients with high blood pressure. Both studies ignore GenoMed's discovery, which is patent-pending, that effective ACE inhibition requires using a water-hating ("hydrophobic") ACE inhibitor at a much higher dose than is conventionally used.
ALLHAT made both mistakes; it used a water-loving ("hydrophilic") ACE inhibitor, lisinopril, at a low dose. PEACE, on the other hand, made only a single, critical mistake. It used a water-hating ("hydrophobic") ACE inhibitor, trandolapril, but at way too low a dose.
Dr. David Moskowitz, GenoMed's Chairman and Chief Medical Officer, said, "These negative studies completely support our findings, which we published in 2002. We showed that using the right ACE inhibitor at the right dose can prevent 90% of kidney failure in this country, but that the dose is absolutely critical."
Dr. Moskowitz continued, "So far, the National Institutes of Health (NIH) has spent over $150 million since 1993 on these two misguided trials. When will they read the literature? How much longer will patients have to suffer from uninformed research?"
About GenoMed
GenoMed, Inc. is a Next Generation DM(tm) [Disease Management] company whose mission is to improve patient outcomes by identifying the genes that cause diseases. GenoMed is currently marketing its protocol for delaying complications like kidney failure due to high blood pressure and diabetes. Eighty million Americans are at increased risk for kidney failure. GenoMed is also marketing its method for delaying emphysema, which 3 million Americans have, and another 60 million smokers are at increased risk of getting.
This winter GenoMed is coordinating a nation-wide influenza trial using the Company's patent-pending protocol, which exploits already existing, FDA-approved drugs. Anyone can enroll simply by clicking on the "Flu trial" link at http://www.genomed.com.
Safe Harbor Statement
This press release contains forward looking statements, including those statements pertaining to GenoMed, Inc.’s (the Company’s) finances and treatments. The words or phrases "ought to,” “should,” "could," “may,” or similar expressions are intended to identify “forward-looking statements” within the meaning of the Private Securities Litigation Reform Act of 1995. Actual results could differ materially from those projected in the forward looking statements as a result of a number of risks and uncertainties, including but not limited to: (a) whether our treatment for influenza will be effective; (b) whether our server holds up to increased demand; (c) our research and development being subject to other economic, regulatory, governmental, and technological factors. Statements made herein are as of the date of this press release and should not be relied upon as of any subsequent date. Unless otherwise required by applicable law, we specifically disclaim any obligation to update any forward-looking statements to reflect occurrences, developments, unanticipated events or circumstances after the date of such statement. |
| What do you think? |
|
 |
|
 |
|
 |
Headlines |
 |
|
